首页> 中国专利> p53基因突变体及其表达的蛋白在制备诊断和治疗肥厚型心肌病的药物中的应用

p53基因突变体及其表达的蛋白在制备诊断和治疗肥厚型心肌病的药物中的应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明公开了p53基因突变体及其表达的蛋白在制备诊断和治疗肥厚型心肌病的药物中的应用，属于生物技术领域。本发明通过实验发现：经超声心动图观察到携带p53N236S突变的小鼠心脏左室后壁和室间隔增厚，离体心重/胫骨长度比值升高，提示p53基因突变小鼠心脏出现了心肌肥厚表型；本发明首次揭示了p53基因突变在调控肥厚型心肌病发病中的新功能，这一发现为突变p53在肥厚型心肌病发病过程中的作用提供新思路和研究方向，为肥厚型心肌病治疗提供新的作用靶点，也为肥厚型心肌病的治疗提供了新的策略。

著录项

公开/公告号CN115044590A

专利类型发明专利
公开/公告日2022-09-13

原文格式PDF
申请/专利权人昆明理工大学;
展开▼

申请/专利号CN202210771636.0
发明设计人旦菊花;罗瑛;张硕杰;苏文华;王露林;谢晓丽;刘静;吴晓明;贾舒婷;唐文如;盛苗苗;周若宇;
展开▼

申请日2022-06-30
分类号C12N15/12;C07K14/47;C12Q1/6883;
代理机构北京盛询知识产权代理有限公司;
代理人相凡
地址 650500 云南省昆明市呈贡区景明南路727号
入库时间 2023-06-19 16:49:13

法律信息

法律状态公告日

法律状态信息

法律状态
2022-09-13

公开

发明专利申请公布

相似文献

专利
中文文献
外文文献

1. C2orf40基因在制备预防、诊断或治疗乳腺肿瘤药物中的应用、表达载体和诊断药物 [P] . 中国专利： CN102925564A . 2013-02-13
2. MYH7‑A934V突变基因用于制备诊断肥厚型心肌病试剂盒的应用 [P] . 中国专利： CN107287317A . 2017-10-24
3. Pharmaceutical composition for epithelial wound prevention and treatment, immunoregulatory pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition, use of insecticide of lectin KM + in the treatment of scarring, use of lectin KM + in preparation of immunoregulatory drug , Use of lectin KM + in formulating antibacterial drugs, use of lectin KM + in formulating antiviral drugs, use of lectin KM + in formulating antifungal drugs, use of lectin KM + in formulating antiparasitic drugs, expression methods, DNA vectors, recombinant organisms , Nucleotide sequences, antibodies, proteins and extranuclear genes [P] . 日本专利： JP2007528869A . 2007-10-18

机译：用于上皮伤口预防和治疗的药物组合物，免疫调节药物组合物，药物组合物，杀虫剂，杀虫剂组合物，凝集素KM +杀虫剂在瘢痕形成中的用途，凝集素KM +在制备免疫调节药物中的用途，凝集素KM +的用途在制备抗菌药物中，凝集素KM +在抗病毒药中的应用，凝集素KM +在抗真菌药中的应用，凝集素KM +在抗寄生虫药中的应用，表达方法，DNA载体，重组生物，核苷酸序列，抗体，蛋白质和核外基因
4. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
5. Nucleic acid sequence, amino acid sequence, replicative cloning vector, isolated host cell expression vector, methods for testing a substance as a therapeutic agent for bone modulation in a host to identify a molecule and a candidate protein involved in bone modulation, to test for hbm activity, for pharmaceutical development to treat bone development disorders, to treat a bone development disorder in an animal, to alter bone development in a host, to treat osteoporosis, to evaluate diagnosis for a genetic predisposition to a bone development disorder, to identify a genetic predisposition to bone development disorders, to express hbm protein in bone tissue, to amplify a nucleotide polymorphism, to identify a regulatory element of an hbm gene, and to modulate bone density and in one patient, diagnostic assay for bone development disorders, bacterial artificial chromosome, isolated nucleic acid segment, nucleic acid, and polypeptide. [P] . BR0017197A . 2003-01-14

机译：核酸序列，氨基酸序列，复制性克隆载体，分离的宿主细胞表达载体，在宿主中测试作为骨调节治疗剂的物质的方法以鉴定参与骨调节的分子和候选蛋白以测试hbm活性，用于药物开发以治疗骨骼发育异常，治疗动物骨骼发育异常，改变宿主的骨骼发育，治疗骨质疏松症，评估对骨骼发育异常的遗传易感性诊断，鉴定遗传易患骨发育障碍，在骨组织中表达hbm蛋白，扩增核苷酸多态性，鉴定hbm基因的调节元件并调节骨密度，并且在一名患者中进行骨发育障碍的诊断测定，细菌人工染色体，分离的核酸片段，核酸和多肽。